UK healthcare workers who receive seasonal influenza vaccination are less likely to contract influenza than their ...

Australian biotech giant CSL said on Tuesday it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of the financial year 2026, alongside job cuts ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Yes, the flu shot is still a thing. And four doctors we spoke to said they recommend you get your flu shot this year.

Australia’s largest pharmaceutical company plans to spin off its Seqirus business into a separate ASX listing in the 2026 ...

The vaccine requires a prescription, which people can obtain by filling out a medical screening questionnaire through the ...

CSL also said it would restart a multi-year share buyback program from FY26, beginning with A$750 million. Chief Executive ...

Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a strong growth ...

SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company ...

New research projects funded to combat avian influenza in swine focus on vaccine development, transmission risks, and biosecurity measures.

After several back-to-school periods spent on guard due to COVID-19, it’s important to remember that other respiratory ...

Long flu refers to lingering symptoms after influenza, fatigue, brain fog, cough, and weakness lasting weeks or months. Early ...